Welcome to our dedicated page for Vertex Pharmaceuticals SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vertex Pharmaceuticals filings document the biotechnology company’s operating results, governance and product-development disclosures. Recent Form 8-K reports include quarterly and annual results releases, selected regulatory and pipeline events involving therapies such as povetacicept, and officer or director transition disclosures.
The company’s proxy materials cover board composition, director nominees, shareholder meeting matters, executive compensation and equity-award information. Vertex filings also provide formal records for disclosure topics tied to its approved medicines, clinical pipeline and governance structure as a Nasdaq-listed operating company.
Vertex Pharmaceuticals Executive Chairman Jeffrey Leiden reported a mix of equity award and tax-related share withholding. On February 17, 2026, he acquired 8,269 shares of common stock at $0.00 per share through a grant described as a restricted stock unit award that fully vested upon grant.
On February 18, 2026, 2,964 shares of common stock at $483.75 per share were disposed of in a tax-withholding disposition, a transaction type used to satisfy tax liabilities by delivering shares rather than an open-market sale. After these transactions, he directly held 38,344 shares of common stock, with an additional 440 shares held indirectly through a 401(k) account.
Vertex Pharmaceuticals CEO Reshma Kewalramani reported mixed equity transactions involving company common stock. She acquired 16,326 shares through a grant or award of restricted stock units, recorded at a price of $0.0000 per share, increasing her direct holdings at that point to 149,813 shares.
On the same date, she disposed of 6,554 shares at $483.75 per share in a tax-withholding disposition to cover exercise price or tax liabilities, leaving her with 143,259 directly held shares afterward. The footnote explains that the restricted stock unit award vests in installments beginning on February 20, 2027, meaning the granted units will become fully available over time rather than immediately.
Vertex Pharmaceuticals executive Mark E. Bunnage reported a mix of stock sales, awards, and tax-related share dispositions. He sold 1,182 shares of common stock at $473.68 per share and 2,437 shares at $489.46 per share in open-market transactions.
He also acquired 2,584 shares through a restricted stock unit award that will vest in installments beginning on February 20, 2027, and disposed of 1,110 shares at $483.75 per share to cover tax obligations. These trades were made under a company-approved Rule 10b5-1 trading plan entered into on November 26, 2025. Following the last reported transaction, he held 8,486 shares of Vertex common stock directly.
Vertex Pharmaceuticals EVP and CMO Carmen Bozic received a grant of 5,375 shares of common stock as a restricted stock unit award that begins vesting on February 20, 2027. On the same date, 1,912 shares at $483.75 each were disposed of to cover tax withholding, leaving her with 41,516 directly owned shares.
Vertex Pharmaceuticals executive Jonathan Biller reported a mix of equity transactions in company stock. On February 17, 2026, he received a grant of 4,135 shares of common stock at $0.00 per share as a restricted stock unit award that vests in installments beginning on February 20, 2027. That same day, 1,505 shares were disposed of at $483.75 per share to cover tax obligations, and 2,476 shares were sold in open-market transactions at an average price of $489.46 per share. On February 18, 2026, he sold an additional 1,244 shares at an average price of $473.68 per share pursuant to an approved Rule 10b5-1 trading plan entered into on February 24, 2025. Following these transactions, he directly held 15,748 shares of Vertex common stock.
Vertex Pharmaceuticals executive Edward Morrow Atkinson III reported a mix of stock sales, awards, and tax-related share disposals. On February 18, he completed an open‑market sale of 817 shares of common stock at an average price of $473.68 per share, leaving him with 20,727 directly owned shares after that sale.
On February 17, he received a grant of 4,962 shares of common stock at no cost, described as a restricted stock unit award that will vest in installments beginning on February 20, 2027. That same day, 2,031 shares were sold in open‑market transactions at an average price of $489.46 per share, and 1,530 shares were disposed of to cover tax obligations at a price of $483.75 per share. The open‑market sales were executed under a company‑approved Rule 10b5‑1 trading plan entered into on August 11, 2025.
Vertex Pharmaceuticals executive Kristen Ambrose reported several stock transactions involving company common shares. She received a grant of 1,809 shares as a restricted stock unit award that will vest in installments beginning on February 20, 2027. On the same date, 598 shares were disposed of to cover tax obligations at a price of $483.75 per share, and 1,557 shares were sold in open-market transactions at $489.46 per share. On the following day, she sold an additional 638 shares at $473.68 per share under a company-approved Rule 10b5-1 trading plan that was entered into on August 8, 2025, leaving her with 7,750 directly owned shares after these transactions.
Vertex Pharmaceuticals executive Charles F. Wagner Jr. reported a tax-related share disposal. On February 13, 2026, he transferred 4,565 shares of common stock at $487.76 per share as a tax-withholding disposition, meaning shares were surrendered to cover taxes rather than sold on the open market. After this transaction, he directly owned 43,715 Vertex shares.
Vertex Pharmaceuticals executive Ourania Tatsis reported two stock transactions involving company common shares. On February 13, 2026, she disposed of 3,804 shares in a tax-withholding transaction at $487.76 per share and completed an open-market sale of 1,500 shares at a weighted average price of $499.99 per share.
The open-market sale was made under a company-approved Rule 10b5-1 trading plan entered into on August 21, 2025. Following these transactions, she directly owned 46,132 shares of Vertex common stock.
Vertex Pharmaceuticals executive Amit Sachdev, EVP Chief Patient & External Affairs Officer, disposed of 3,548 shares of common stock on February 13, 2026 at $487.76 per share in a tax-withholding disposition. After this, he directly held 65,393 shares, with additional indirect holdings of 9,301 shares in a trust and 882 shares in a 401(k).